Compare GSK plc (GSK) vs International Business Machines Corp (IBM) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

IBM's stock is trading at $213.46, down 1.66% for the day, following a significant 25% drop after a preliminary Q2 2026 earnings warning. The company reported strong profitability with a 15.61% net income margin and has beaten earnings estimates for the last three quarters. Technical indicators show a bearish trend, with the current price near the pivot point of $214. Recent news highlights concerns over AI's impact on enterprise spending and a securities fraud investigation.

The outlook is mixed: solid fundamentals and a consensus price target of $310.21 suggest long-term upside, but near-term risks from softer demand and legal scrutiny warrant caution. Investors should weigh the high ROE of 35.93% against volatility from shifting tech budgets and potential earnings miss in Q2.